The timing and extent of treatment depend on the clinical manifestations. Because accelerated bone maturation can lead to premature closure of bone epiphyses and short stature, androgen therapy should be used cautiously in children and only by specialists aware of the adverse effects on bone maturation. Skeletal maturation must be monitored every 6 months by radiography of the hand and wrist. Artificial induction of puberty is undertaken only after boys reach age 15 to 17 years and after hypothalamic and pituitary function has been assessed. A 4- to 6-month trial of androgen therapy is implemented, followed by a similar period of rest for reevaluation. If prolonged therapy is required, testosterone cypionate is used, 50 to 400 mg IM every 2 to 4 weeks. It should be given deep in the IM. Inspect vials visually for particulate matter and discoloration before administration, and warm and shake the vial to dissolve any crystals that may have formed during storage. It takes 3 or 4 years for sexual development to occur, and plasma testosterone levels should be monitored and dosages adjusted as needed to maintain normal levels; if the serum testosterone level is below the normal range, the provider will adjust the dose upward. Therapy may be lifelong.

Testosterone may be administered buccally, nasally, transdermally, or parenterally. Drug selection depends on the balance of growth and sexual maturation desired and on the preferred route of administration. A buccal mucoadhesive system is available that provides a 30-mg dose every 12 hours. Advise the patient to place the rounded surface of the system against the gum above an incisor tooth and hold it firmly in place with finger over the lip and against the product for 30 seconds. To remove, slide gently downward toward the tooth to avoid scratching the gums. Sites must be rotated with each application. If the product falls off within the 12-hour dosing interval, or if it falls out of position within 4 hours before next dose, remove it and apply a new system. The patient should not chew or swallow the system. Advise the patient to regularly inspect gums where the system has been applied. Testosterones are considered Schedule III controlled substances.

Transdermal testosterone (TT) patches achieve adequate serum concentrations when applied to the arm, back, or upper buttocks. TT patches can be applied to any healthy skin site other than the scrotum or bony areas. Daily application of one to two TT 2 mg/24 h or 4 mg/24 h skin patches at 10 PM results in serum testosterone concentrations approaching those of healthy young men. The first day of dosing results in morning serum testosterone concentrations within the normal range. There is no testosterone accumulation with continued use. After removal of TT patches, hypogonadal status returns within 24 hours. Keep testosterone gel out of reach of children.

Testosterone gel is applied to clean dry skin of shoulders or upper arms. It should not be applied to the genitals. Hands should be thoroughly washed with soap and water following application. Testosterone gel carries a boxed warning, as it can be transferred to others through personal contact with skin or clothing. Children should avoid contact with unwashed application sites or application sites not covered by clothing. Children can experience virilization from secondary exposure. Caution is advised.

Other side effects of androgen therapy include abdominal pain, nausea, insomnia, diarrhea or constipation, hives or redness at the injection site, increased salivation, mouth soreness, and increased or decreased sexual desire. Advise the patient to notify the health care provider if side effects persist, worsen, or are bothersome.

Virilization refers to the development of male secondary sex characteristics in women or hypogonadal males. Such characteristics include growth of facial hair, acne and skin oiliness, and vocal huskiness. Menstrual irregularities or amenorrhea, suppressed ovulation or lactation, baldness or increased hair growth (hirsutism), and hypertrophy of the clitoris may develop in women undergoing androgen therapy. Although most adverse effects slowly reverse themselves after short-term therapy is completed, vocal changes may be permanent. With long-term therapy, as in the treatment of breast cancer, adverse effects may be irreversible.

Children may experience profound virilization as well as impaired bone growth. During pregnancy, androgens can cross the placenta and cause masculinization of the fetus. Virilization can occur in those secondarily exposed to testosterone gel and may cause teratogenic effects in fetuses. Women and children should not handle the gel and should avoid contact with application sites in men using testosterone gel.

Less frequent adverse effects include dizziness, weakness, changes in skin color, frequent headaches, confusion, respiratory distress, depression, pruritus, allergic skin rash, edema of the lower extremities, jaundice, bleeding, paresthesias, chills, polycythemia, muscle cramps, and sodium and water retention. Hepatocellular carcinoma can occur in patients who have received selected androgens for long-term therapy and in cases of abuse of androgenic hormones by athletes.

Serum cholesterol may become elevated during androgen therapy. Other alterations in laboratory tests include increased hematocrit, altered thyroid and liver function tests, and elevated urine 17-ketosteroids (a by-product of the breakdown of androgens). Rare complications of long-term therapy include hepatic necrosis, hepatic peliosis (blood-filled cysts), hepatic tumors, and leukopenia.

Caution must be exercised when using androgen therapy in individuals with hypertension, hypercholesterolemia, coronary artery disease, renal disease, or seizure disorder. It is used with caution in infants and prepubertal children because of the potential for growth disturbances and in older men because of their increased risk for BPH and prostate cancer.